AUTHOR=Qi Aoshuang , Ju Mingyi , Liu Yinfeng , Bi Jia , Wei Qian , He Miao , Wei Minjie , Zhao Lin 

TITLE=Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 27 - 2021

YEAR=2021

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2021.600727

DOI=10.3389/pore.2021.600727

ISSN=1532-2807

ABSTRACT=Background: Complex immune processes are involved in the development and progression of breast cancer (BC). As a single biomarker is unlikely to adequately reflect the complex interplay between immune cells and cancer, there has been no investigation to find a antigen processing and presentation-related and robust signature to predict the survival outcome of BC patients in the aspect of tumor immunology. We aimed to develop an accurate gene signature based on immune related genes for prognosis prediction of BC. 
Methods: The information of BC patients obtained from The Cancer Genome Atlas (TCGA). Gene Set Enrichment Analysis (GSEA) confirmed the gene set of antigen processing and presentation contributed to BC. Cox proportional regression, multivariate Cox regression and stratified analysis identified prognostic power of the gene signature. Differentially expressed mRNAs between high- and low-risk groups were analyzed by KEGG.
Results: The three-gene signature (HSPA5 (heat shock protein family A member 5), PSME2 (proteasome activator subunit 2), HLA-F (major histocompatibility complex, class I, F)) were significantly associated with overall survival (OS). HSPA5, PSME2 were protective type with HR<1 and HLA-F was risky type with HR>1. Risk score, cancer status, ER, PR and PDL-1 were independent prognostic indicators. KIT and ACACB may paly important role in the mechanism of gene signature regulates the prognosis of BC.
Conclusions: The proposed three-gene signature is a promising biomarker for estimating survival outcome in BC patients.